Clarient Names Laboratory Industry Expert, James V. Agnello, as New Chief Financial Officer
ALISO VIEJO, Calif., June 1 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, announced today the appointment of James V. Agnello as Senior Vice President and Chief Financial Officer effective June 19, 2006.
Mr. Agnello replaces Jay Roberts, who has been serving as Clarient's Interim CFO since February, 2006.
brings over 15 years of service in laboratory services businesses to his
He most recently served as Controller and Chief Accounting Officer and Division Chief Financial Officer at Teleflex, Inc. (NYSE: TFX), a $2.5 billion global manufacturing and engineering conglomerate.
Previously he served as Senior Vice President and Chief Financial Officer for Impath, Inc., a science-based health care services company, responsible for all areas of finance and administration, including SEC reporting.
Mr. Agnello also served as Vice President and Controller for SmithKline Beecham's $1.5 billion clinical laboratory division prior to its merger with Quest Diagnostics, after serving in a variety of senior finance positions throughout the company.
"We are extremely pleased to have Jim join the Clarient organization," said Ron A. Andrews, President and CEO.
possesses the rare combination of public company experience, reference laboratory service experience and exceptional leadership skills that we were looking for to fill this important position.
"I am very pleased to be joining Clarient
at this point in the Company's life," said Mr. Agnello
Subject to approval of its Board of Directors, Clarient
will be granting Mr. Agnello
non-qualified options to purchase 300,000 shares of its common stock for an exercise price equal to the fair market value of Clarient's common stock on the date of grant (which options will vest over a five year period), in addition to other compensation and benefits commensurate with his
position and responsibilities the material terms of which are described in Clarient's Current Report on Form 8-K filed on the date hereof with the Securities and Exchange Commission